Holen Sie sich die Stockscreener-App
25.93
3.68%
0.92
Handel nachbörslich:
25.93
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Earnings Call: Growth, Gene Therapy and Risk - TipRanks
Ultragenyx Pharmaceutical Inc. 2024 SEC Filing: Financial Information, Forward-Looking Statements, and Market Risks - Minichart
Ultragenyx investors can watch CFO at Bank of America panel May 12 - Stock Titan
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference - ChartMill
Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares - Investing.com
Ultragenyx (NASDAQ: RARE) CMO sells shares to cover RSU taxes - Stock Titan
Ultragenyx outlines $730M-$760M 2026 revenue as it targets two gene therapy PDUFAs in August and September - MSN
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect - Yahoo Finance
Wells Fargo & Company Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Two FDA decisions by September put Ultragenyx gene therapies in focus - Stock Titan
Wedbush Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Has $323,000 Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Privium Fund Management B.V. - MarketBeat
Ultragenyx Pharmaceutical Q1 Loss Widens, Revenue Falls; Shares Down Pre-Bell - marketscreener.com
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS - MarketBeat
Earnings call transcript: Ultragenyx Q1 2026 results miss forecasts By Investing.com - Investing.com Canada
Ultragenyx (NASDAQ: RARE) Q1 loss widens as R&D and restructuring costs rise - Stock Titan
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript - Benzinga
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance Singapore
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
ULTRAGENYX PHARMACEUTICAL ($RARE) Releases Q1 2026 Earnings - Quiver Quantitative
Ultragenyx: Q1 Earnings Snapshot - marketscreener.com
Gene therapy reviews and Q1 2026 results at Ultragenyx (RARE) - Stock Titan
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update - The Manila Times
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 Shares - MarketBeat
Ultragenyx CFO Howard Horn sells $116,606 in company stock By Investing.com - Investing.com Australia
Ultragenyx CFO Howard Horn sells $116,606 in company stock - Investing.com
Ultragenyx (RARE) CFO trims stake with 4,683-share open-market sale - Stock Titan
MSN Money - MSN
Mucopolysaccharidoses Market to Reach USD 4,389.85 Million - openPR.com
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Momentum And Ongoing Losses - Sahm
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street Zen - MarketBeat
Affiliate sales notice for RARE (NASDAQ: RARE) lists recent Howard Horn transactions - Stock Titan
Pictet Asset Management Holding SA Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx falls as guidance trails consensus amid job cuts - MSN
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Rare's DTX301 meets first key goal in Phase III OTC deficiency study - MSN
Vanguard Portfolio Management discloses 5.5% stake in Ultragenyx (RARE) - Stock Titan
Ultragenyx earnings: What to watch as pipeline faces key test By Investing.com - Investing.com India
Ultragenyx earnings: What to watch as pipeline faces key test - Investing.com
Barclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat
RARE Maintained by Barclays -- Price Target Lowered to $43 - GuruFocus
Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial - Yahoo Finance
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update - marketscreener.com
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rare rises as FDA accepts resubmitted BLA for Sanfilippo syndrome - MSN
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
FDA decision on UX111 gene therapy for Sanfilippo expected in September - Sanfilippo Syndrome News
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA - MSN
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):